Table 1.
Ongoing Selinexor Studies in Multiple Myeloma.22
| Phase (NCT Identifier) | Selinexor Dosing | Additional Therapeutic Agents | Prior Lines of Therapy |
|---|---|---|---|
| 1/2 (NCT02199665) |
60 mg twice/week | Carfilzomib Dexamethasone |
2 (must include PI and IMiD) |
| 1 (NCT02831686) |
Twice/week for 3 weeks, 1 week off | Ixazomib Dexamethasone |
≥ 1 (must include PI and IMiD) |
| ½ (NCT02186834) |
80 mg loading dose followed by 60 mg once/week to 80 mg twice/week | Liposomal doxorubicin Dexamethasone |
≥ 2 (must include PI and lenalidomide) |
| ½ (NCT02780609) |
Dose escalation starting with 40 mg 2-3 hours prior to melphalan for autologous HCT (day −3 and −2) | High dose melphalan Dexamethasone |
< 4 |
| 2 (NCT03589222) |
100 mg once/week | Bortezomib Daratumumab Dexamethasone |
≥ 3 (must include PI and IMiD) |
| 3 (NCT03110562) |
100 mg once/week | Bortezomib Dexamethasone |
1-3 |
Abbreviations: PI, proteasome inhibitor; IMiD, immunomodulatory agent; HCT, hematopoietic cell transplantation.